Download PDF
Thromb Haemost 2013; 110(02): 205-212
DOI: 10.1160/TH13-02-0150
Clinical Focus
Schattauer GmbH

Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategies

Jay Desai
1   Department of Medicine (Division of Gastroenterology), New York University, New York, New York, USA
,
Jennifer M. Kolb
2   Department of Medicine (Division of Gastroenterology), Icahn School of Medicine at Mount Sinai, New York, New York, USA
,
Jeffrey I. Weitz
3   Departments of Medicine and Biochemistry and Biomedical Sciences, McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
,
James Aisenberg
2   Department of Medicine (Division of Gastroenterology), Icahn School of Medicine at Mount Sinai, New York, New York, USA
› Author Affiliations Financial support: Jay Desai and Jennifer M. Kolb were supported by grants from the Digestive Disease Research Foundation.
Further Information

Publication History

Received: 19 February 2013

Accepted after minor revision: 27 April 2013

Publication Date:
04 December 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Kwong LM. Rivaroxaban, an oral, direct factor Xa inhibitor: a new option for thromboprophylaxis. Orthopedics 2012; 35: e932-938.
    CrossrefPubMedGoogle Scholar
  • 2 Lassen MR, Raskob GE, Gallus A. et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375: 807-815.
    CrossrefPubMedGoogle Scholar
  • 3 Connolly S, Ezekowitz M B C, Salim Y. et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. New Engl J Med 2009; 361: 1139-1151.
    CrossrefPubMedGoogle Scholar
  • 4 Patel M, Mahaffey K, Garg J. et al. Rivaroxaban versus Warfarin in Nonvavular Atrial Fibrillation. New Engl J Med 2011; 365: 883-891.
    CrossrefPubMedGoogle Scholar
  • 5 Granger C, Alexander J, McMurray J. et al. Apixaban versus Warfarin in Patients with Atrial Fribrillation. New Engl J Med 2011; 365: 981-992.
    CrossrefPubMedGoogle Scholar
  • 6 Ganetsky M, Babu KM, Salhanick SD. et al. Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol 2011; 07: 281-287.
    CrossrefPubMedGoogle Scholar
  • 7 Raghavan N, Frost CE, Yu Z. et al. Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans. Drug Metab Dispos 2009; 37: 74-81.
    CrossrefPubMedGoogle Scholar
  • 8 Blech S, Ebner T, Ludwig-Schwellinger E. et al. The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans. Drug Metabol Disp 2008; 36: 386-399.
    CrossrefPubMedGoogle Scholar
  • 9 Weinz C, Schwarz T, Kubitza D. et al. Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and Humans. Drug Metab Dispos 2009; 37 (05) 1056-64.
    CrossrefPubMedGoogle Scholar
  • 10 Coleman CI, Sobieraj DM, Winkler S. et al. Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation. Int J Clin Pract 2012; 66: 53-63.
    CrossrefPubMedGoogle Scholar
  • 11 Rubin T, Murdoch M, Nelson DB. Acute GI bleeding in the setting of supratherapeutic international normalized ratio in patients taking warfarin: endoscopic diagnosis, clinical management, and outcomes. Gastrointest Endoscopy 2003; 58: 369-373.
    PubMedGoogle Scholar
  • 12 Di Caro S, May A, Heine DGN. et al. The European experience with double-balloon enteroscopy: indications, methodology, safety, and clinical impact. Gastrointest Endoscopy 2005; 62: 545-550.
    CrossrefPubMedGoogle Scholar
  • 13 Gay G, Delvaux M, Rey JF. The role of video capsule endoscopy in the diagnosis of digestive diseases: a review of current possibilities. Endoscopy 2004; 36: 913-920.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Zuckerman GR, Prakash C, Askin MP. et al. AGA technical review on the evaluation and management of occult and obscure gastrointestinal bleeding. Gastroenterology 2000; 118: 201-221.
    CrossrefPubMedGoogle Scholar
  • 15 Schulman S, Angerås U, Bergqvist D. et al. Definition of major bleeding in clinical investigations of antihaemostatic medicinal products in surgical patients. J Thromb Haemost 2010; 08: 202-204.
    CrossrefPubMedGoogle Scholar
  • 16 Eikelboom JW, Wallentin L, Connolly SJ. et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363-2372.
    CrossrefPubMedGoogle Scholar
  • 17 Nessel C, Mahaffey K, Piccini JP. et al. Incidence and Outcomes of Gastrointestinal Haemorrhage in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: Results From the ROCKET AF Trial (abstract). Chest 2012; 142: 84A.
    CrossrefPubMedGoogle Scholar
  • 18 Southworth MR, Reichman ME, Unger EF. Dabigatran and Postmarketing Reports of Bleeding. New Engl J Med. 2013 Epub ahead of print.
    PubMedGoogle Scholar
  • 19 European Medicines Agency Human medicines. European Medicines Agency updates patient and prescriber information for Pradaxa [Internet]. Available from: http://www.ema.europa.eu/ema/ index.jsp?curl=pages/medicines/human/public_health_alerts/2012/05/human_pha_detail_000061.jsp&mid=WC0b01ac058001d126
    PubMedGoogle Scholar
  • 20 Drug Safety and Availability FDA Drug Safety Communication: Update on the risk for serious bleeding events with the anticoagulant Pradaxa (dabigatran) [Internet]. Center for Drug Evaluation and Research. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm326580.htm
    PubMedGoogle Scholar
  • 21 Lim YJ, Yang C-H. Non-steroidal anti-inflammatory drug-induced enteropathy. Clin Endoscopy 2012; 45: 138-144.
    PubMedGoogle Scholar
  • 22 FDA Advisory Committee Briefing Document. Boehringer Ingelheim. Dabigatran etexilate 2010; 1-168.
    PubMedGoogle Scholar
  • 23 Dans AL, Connolly SJ, Wallentin L. et al. Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial. Circulation 2013; 127: 634-640.
    CrossrefPubMedGoogle Scholar
  • 24 Goldstein JL, Eisen GM, Lewis B. et al. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment Pharmacol Therapeut 2007; 25: 1211-1222.
    CrossrefPubMedGoogle Scholar
  • 25 Laine L, Maller ES, Yu C. et al. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology 2004; 127: 395-402.
    CrossrefPubMedGoogle Scholar
  • 26 Kernan L, Ito S, Shirazi F. et al. Fatal gastrointestinal haemorrhage after a single dose of dabigatran. Clin Toxicol 2012; 50: 571-573.
    CrossrefPubMedGoogle Scholar
  • 27 Fellows SE, Rosini JM, Curtis JA. et al. Haemorrhagic Gastritis with Dabigatran in a Patient with Renal Insufficiency. J Emerg Med 2012; 44: e221-e225.
    PubMedGoogle Scholar
  • 28 Wychowski MK, Kouides P a. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacotherapy 2012; 46: e10.
    PubMedGoogle Scholar
  • 29 Pisters R, Lane D, Nieuwlaat R. et al. A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100.
    CrossrefPubMedGoogle Scholar
  • 30 Garcia D, Barrett YC, Ramacciotti E. et al. Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost 2013; 11: 245-252.
    CrossrefPubMedGoogle Scholar
  • 31 Frost C, Wang J, Nepal S. et al. Apixaban, an oral, direct factor Xa inhibitor: single-dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 2013; 75: 476-487.
    CrossrefPubMedGoogle Scholar
  • 32 Van Ryn J, Stangier J, Haertter S. et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Davila RE, Rajan E, Adler DG. et al. ASGE Guideline: the role of endoscopy in the patient with lower-GI bleeding. Gastrointest Endoscopy 2005; 62: 656-660.
    CrossrefPubMedGoogle Scholar
  • 34 Dunn CJ, Goa KL. Fibrin sealant: a review of its use in surgery and endoscopy. Drugs 1999; 58: 863-886.
    CrossrefPubMedGoogle Scholar
  • 35 Leung E-LKi, Lau JYW. New endoscopic haemostasis methods. Clin Endoscopy 2012; 45: 224-229.
    PubMedGoogle Scholar
  • 36 Pragst I, Zeitler SH, Doerr B. et al. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost 2012; 10: 1841-1848.
    CrossrefPubMedGoogle Scholar
  • 37 Dumkow LE, Voss JR, Peters M. et al. Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma. J Am Soc Health System Pharmacists 2012; 69: 1646-1650.
    PubMedGoogle Scholar
  • 38 Godier A, Miclot A, Le BBonniec. et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012; 116: 94-102.
    CrossrefPubMedGoogle Scholar
  • 39 Stangier J, Rathgen K, Stähle H. et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, singlecentre study. Clin Pharmacokinet 2010; 49: 259-268.
    CrossrefPubMedGoogle Scholar
  • 40 Van Ryn J, Litzenburger T, Schurer J. Reversal of Anticoagulant Activity of Dabigatran and Dabigatran-induced Bleeding in Rats by a Specific Antidote (Antibody Fragment) (abstract). Circulation. 2012 Available from: http://circ.ahajournals.org/cgi/content/meeting_abstract/126/21_MeetingAbstracts/A9928
    PubMedGoogle Scholar
  • 41 Kwok A, Faigel DO. Management of anticoagulation before and after gastrointestinal endoscopy. Am J Gastroenterol 2009; 104: 3085-3097 quiz 3098.
    CrossrefPubMedGoogle Scholar
  • 42 Weitz JI, Quinlan DJ, Eikelboom JW. Periprocedural Management and Approach to Bleeding in Patients Taking Dabigatran. Circulation 2012; 126: 2428-2432.
    CrossrefPubMedGoogle Scholar
  • 43 Healey JS, Eikelboom J, Douketis J. et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation 2012; 126: 343-348.
    CrossrefPubMedGoogle Scholar